Palatin Technologies, Inc. (0KF3) Earnings Call Transcript & Summary
May 17, 2021
Earnings Call Speaker Segments
Operator
operatorGood afternoon, everyone, and thanks for joining us for Palatin’s conference call on operating results for the third quarter of fiscal year 2021. Please note that this session is being recorded. Before we get into our remarks, I want to remind everyone that anything Palatin states that isn’t a historical fact may constitute a forward-looking statement. Such statements rest on assumptions that might or might not turn out to be correct, and actual results could differ materially from what is anticipated because of the various risks and uncertainties covered in the company’s latest filings with the Securities and Exchange Commission. We ask that you weigh those risks and uncertainties carefully when evaluating these forward-looking statements and Palatin’s prospects. At this point, I’ll hand today’s call to our host, Dr. Carl Spana, Palatin’s President and Chief Executive Officer. Sir, the floor is yours.
Carl Spana
executiveThanks. Good morning, everyone, and welcome to the call for Palatin Technologies' third quarter of fiscal year 2021. This is Dr. Carl Spana, President and CEO of Palatin. Joining me today is Steve Wills, who serves as Palatin's Executive Vice President, Chief Financial Officer and Chief Operating Officer. During this call, we'll be sharing financial and operating updates. At this point I'll hand things over to Steve, who will cover the financial updates along with an update on the exciting and significant progress we're achieving with Vyleesi. Steve?
Steve Wills
executiveThanks, Carl, and morning to everyone. Turning to the financial results for our third quarter of 2021 — that's Palatin's quarter that closed on March 31, 2021 — total net revenue came to $88,741, all of it net product revenue from Vyleesi. For the third quarter of 2020, no revenue was reported. Vyleesi gross sales reached $1,780,020, and net product revenue was again $88,741 after allowances and accruals; in the prior quarter, which ended December 31, 2020, gross sales were $943,950, with net product revenue of negative $163,971 after allowances and accruals. Operating expenses totaled $6.6 million, versus $5.7 million in the same period of 2020, with the rise driven mainly by commercial expenses tied to Vyleesi. Palatin's net loss came to $5.7 million, or $0.02 per share, against a net loss of $5.4 million, or $0.02 per share, in the comparable quarter of 2020. At March 31, 2021, Palatin held $68.6 million in cash and cash equivalents plus $1.9 million in accounts receivable, compared with $82.9 million in cash and cash equivalents and no accounts receivable at June 30, 2020. Palatin carries no outstanding debt. On Vyleesi — our FDA-approved product for hypoactive sexual desire disorder, or HSDD — for the quarter ended March 31, 2020 over the prior quarter ended December 31, 2020, gross product sales rose 89%; net revenue rose 154% and prescriptions rose 24%, which are very significant numbers for the quarter.
Steve Wills
executiveWe expect geo-targeted marketing work to boost engagement among healthcare providers and consumers. Our existing digital campaign applications are reaching thousands of healthcare providers and millions of premenopausal women each month, and that has driven more website and telemedicine traffic along with more conversions. Expanding access and reimbursement coverage remains our focus. We estimate that Vyleesi has reached roughly 75% of commercially insured lives and about 50% of commercial formulary coverage, which includes two of the three major pharmacy benefit managers and many regional plans. Higher prescription volumes plus broader access and reimbursement coverage have produced more favorable gross-to-net adjustments and, for the first time, positive quarterly net product revenue. I'll now hand the call back to Carl. Carl?
Carl Spana
executiveThank you, Steve. We're still carrying out our work under the conditions created by the COVID-19 pandemic, which remains ongoing. As of today, we believe the changes we've implemented have enabled us to keep moving forward with our preclinical, clinical, and commercial programs, and in doing so we've maintained safety for our employees, patients, healthcare providers, and partners. As Steve mentioned in his presentation, we've achieved substantial progress in building out and strengthening the commercial infrastructure for Vyleesi and in assembling an excellent, motivated commercial team. The adjustments we've made have enhanced the patient experience, patient access, relationships with prescribers, and the profitability of Vyleesi. The quarter's results show their positive effects on prescriptions and revenue. We're now well positioned to demonstrate Vyleesi's potential value in a cost-effective manner and to achieve our ultimate objective — relicensing Vyleesi to a committed partner, ensuring that Vyleesi remains available as a treatment option for premenopausal women with HSDD, or hypoactive sexual desire disorder, and securing a return on our investment. During the quarter, we updated our website and logo to reflect our shift toward a focus on developing therapeutics that target the melanocortin system's ability to resolve or turn down inflammation and reduce fibrosis.
Carl Spana
executiveDrawing on our deep technology and experience in the biology, chemistry, and development of therapeutics that interact with the body's melanocortin system, we're building a portfolio of therapeutics that we believe will hold significant potential for treating diseases affecting the eye, gastrointestinal system and kidney. The melanocortin system plays a critical role in protecting the eye from harmful inflammation. And we're developing multiple products for ocular diseases. Properly delivered PL9643 is our melanocortin agonist for treating ocular diseases that affect the tissues comprising the anterior segment of the eye. The first indication for PL9643 is dry eye disease, and we have people who reported positive data on a Phase 2 dry eye disease clinical study. We're currently pleased to have been selected to present the detailed data at a podium session at the Association for Research in Vision and Ophthalmology 2021 Annual Meeting in May. The presentation was well received by the ophthalmology community. We're advancing topical PL9643 into a Phase 3 study in moderate-to-severe dry eye disease patients, which is scheduled to begin in the second half of calendar 2021. To support this program, we have scheduled an end of Phase 2 meeting with the FDA to discuss the details of the Phase 3 program.
Carl Spana
executiveThe emerging profile for PL9643 — with its fast therapeutic onset and excellent ocular tolerability — offers a potentially distinct advantage in dry eye therapy. Should those results be confirmed in the upcoming Phase 3 clinical study, we believe PL9643 could potentially achieve substantial penetration into the multi-billion dollar dry eye disease markets. During the past quarter, we also kept advancing our preclinical programs for retinal and corneal diseases. Our data from various preclinical models of retinal disease was also presented at ARVO as a poster. If you'd like to learn more about our ocular programs, you can visit our new website, where you'll find both of the oral presentations. In addition, we are hosting a Key Opinion Leader presentation on May 21, which is focused on our ocular programs, PL9643 clinical data, design of the PL9643 Phase 3 clinical study and the role of the melanocortin system in ocular diseases. Moving on to our PL8177 oral formulation for ulcerative colitis, we are conducting activities required to initiate a Phase 2 proof-of-concept study which is targeted to start patient enrollment in the second half of 2021, with potential data readout in 2022. This will be our first clinical study designed to evaluate the potential of a selective melanocortin 1 receptor agonist as a treatment for ulcerative colitis.
Carl Spana
executiveThis study is going to assess how safe oral PL8177 is and whether it has potential efficacy, and positive study results will back our push to license oral PL8177. Then, building on the research we've done on the natriuretic peptide system, our drug candidate PL-3994 — a selective natriuretic peptide receptor A agonist — is now being evaluated in a Phase 2a clinical study involving heart disease patients with preserved ejection fraction. That clinical study is run in cooperation with two major academic medical centers, and a grant from the American Heart Association supports it. Enrollment is ongoing, and we expect preliminary data in early 2022. More details on our programs are available on our new website, www.palatin.com. Over the past quarter, we kept making significant progress across all our programs, and our healthy cash position will let us emerge from the pandemic in a strong position. Under Steve Wills' direction, our Vyleesi commercial activities have made significant progress. Those changes are starting to have a positive impact on growing Vyleesi prescriptions and revenue. For PL9643, a topical treatment for dry eye disease, we are carrying out the activities required to begin a Phase 3 study, second half of this calendar year.
Carl Spana
executiveThis also involves getting ready for an end of Phase 2 meeting with the FDA. At the Association for Research in Vision and Ophthalmology 2021 Annual Meeting, we gave two presentations: one detailed the results of the PL9643 Phase 2 clinical trial in dry eye disease, and the other covered preclinical data on our melanocortin agonist for retinal diseases. We're continuing to expand a product portfolio of melanocortin-based ocular therapeutics, and we expect to launch a clinical development program for a second ocular indication beginning in the second half of 2021. We're still on schedule to begin a Phase 2 proof-of-concept clinical study of an oral formulation of PL8177 in ulcerative colitis patients, with a target start in the second half of calendar 2021. Lastly, on May 21, 2021, we're holding a Key Opinion Leader webinar focused on melanocortin agonists for treating ocular indications; it will center mainly on PL9643 and the data from our recently completed Phase 2 clinical trial for dry eye disease, and will introduce our expanding portfolio of melanocortin agonists for treating the harmful effects of inflammation in the eye. Looking ahead to the rest of 2021, we have a robust pipeline of novel clinical candidates, and our focus stays on advancing them.
Carl Spana
executiveTo wrap up, Steve and I want to express our appreciation to everyone at Palatin, along with all of our partners, for their ongoing commitment to moving our programs forward. At this point, we'll open up the call for questions.
Operator
operatorThanks. <<operator_script>> Our first question comes from John Newman at Canaccord. Go right ahead.
John Newman
analystHey everyone, thanks for taking my question. I just have a question about Vyleesi — it seems like you folks have been making some adjustments there that have definitely been pushing things in the right direction. I'm just curious what we should expect for the remainder of the year, in terms of the continued efforts you're making. And I'm also curious whether you think that, sort of coming out of COVID, there might be a positive tailwind there as well. I'm not sure if this is a product where face-to-face interaction with the physician is required, but I just wanted to ask about that. Thanks.
Steve Wills
executiveOkay, thanks John. Steve here. Look, I can't offer a Nostradamus-style forecast for the remainder of the year, but the 331 per quarter — we expect that to be replicated going forward. On the pandemic, I mean, in-person interaction, I think that's always preferable. Palatin, much like most other firms, is doing the best it can given the limited face-to-face. At this point we're having some in-person contact, though the bulk of it is still Zoom or video streaming. So our expectation is that as the market opens up further thanks to the pandemic and things get a bit better for people, with greater access to in-person meetings, we'll likewise see somewhat stronger uptake in our prescription care.
John Newman
analystAnd I think you've noticed a better gross-to-net adjustment. Would you expect that to keep getting better going forward?
Steve Wills
executiveSure. That was, I mean, one of the A items Carl and I focused on really early, even with prescriptions rising, Palatin brings in the largest net revenue per script thanks to better insurance coverage. So we've worked hard to grow our covered lives and our formulary coverage, and what that gives us is a more favorable gross to net. Our strategy right now is to keep the copay program going. So for patients, the first dose costs zero dollars out of pocket. And any dose after that is no more than $99 out of pocket. Now that doesn't mean we can't collect the insurance. So as I mentioned, I think we've done a pretty good job of expanding coverage in that area. But we've also gotten better on the processes. We've swapped out one of our specialty pharmacies. And I feel we're working quite closely with the pharmacies to make sure the processes are as streamlined and as efficient as possible for both the health care provider and also for the patient.
John Newman
analystAll right, that's helpful. I was also hoping for an update on how partnership efforts are going. I realize your team has put a lot of effort into bringing the prescriptions to a solid place. Beyond that, I'd like to hear your thoughts on what a partner could mean for Vyleesi. Thanks.
Steve Wills
executiveThanks, John. And — no question about it, that is Palatin’s strategy. It is Carl and Steve’s strategy: relicense the product within the U.S. and widen collaborations across the other regions as well. Those discussions and negotiations keep moving forward and remain ongoing. I feel quite comfortable that the first quarter results are going to support those discussions, since we are demonstrating very meaningful progress. We are demonstrating that the brand carries value and that our investment stays limited. So our approach is to locate a committed partner operating in the female health care space, one with the kind of infrastructure that lets you either place it behind this product as a standalone product, or add it onto other existing products that you already have. So we believe the first quarter results matter a great deal with respect to those negotiations, but they are advancing.
John Newman
analystAll right, thanks a lot.
Operator
operatorOur following question comes from Joe Pantginis at H.C. Wainwright. Go right ahead.
Joe Pantginis
analystMorning, everyone, and thanks for the question. I'd like to zero in on how PL-9643 is evolving, since you now have a shot at a second possible commercial product. I realize we'll hear more about the clinical program at the end of the week, but first I'd like to know whether you can say a bit more about the end points of the planned Phase 3 study compared with the Phase 2 trial that read out in December, 2020, and what sorts of adjustments you made. What I really want to do here, though, is connect this to business development, or possible business development, around this asset, because since you're now heading into end of Phase 2 meetings with the FDA and aiming to begin a Phase 3 by the end of the year, a potential partner might want a say in how the program is designed or conducted, so I just wanted to put those two together? Thanks.
Carl Spana
executiveThanks, Joe. Carl here. A few points. For anyone listening who isn’t familiar with the dry eye disease landscape — it’s a variable regulatory environment. One approach to demonstrating efficacy is simply to consider the signs and symptoms. Dry eye disease brings symptoms like scratchy eyes, dry eyes, and painful burning. All of those are symptoms, while the others are signs — and signs are more indicative of the underlying inflammation or damage that may be happening to the tissues in the eye and the surface of the cornea and the conjunctiva — whatever you want to call it. So the strategy is that if you demonstrate an improvement in a sign and a symptom, that serves as the basis for approval of the product. There’s no — so having said that, we will be examining multiple signs and symptoms in the Phase 3 program. And I don’t want to get too far into the details, because I think we have some great people on the call coming up on Friday who will really walk you through the data, how that was translated into the design of the Phase 3 trial, the design that we’re using, which is a little bit innovative, and how that’s going to play out.
Carl Spana
executiveBut it's enough to say that we will be examining the signs and symptoms. And once more, several of those were drawn from the Phase 2 data. So the ones emerging from that Phase 2 data — where our results are strongest in a moderate to severe patient population, which is the group we're focused on — those will form the foundation for both the primary endpoint and the key secondary endpoint. So these will include things like improving ocular pain, conjunctival staining, and inferior corneal fluorescein staining. Those are the kinds of things on which we demonstrated very strong results in the Phase 2 study. And they'll serve as the basis for Phase 3, though how they will be structured and analyzed — I think I'll likely leave a little suspense until the end of the week, because I think we have some really great guys who can walk you through it. And I think we've designed a very, very innovative program that reduces our risk as we move forward into Phase 3, and we're quite excited about it. So I'll stop there on that subject. When it comes to licensing and so forth, Joe, we learned a lot through Vyleesi and — although we're not necessarily in a great hurry to license this asset among the ocular assets as we come through.
Carl Spana
executiveWhat I mean is, we have the capital to get through the Phase 3 clinical study. So even though we're receiving interest and we're beginning to, obviously, engage with potential partners, I think that what we're doing, based on the feedback we're getting, is the kind of thing they're comfortable with. So I don't believe there will be much change in the trial design if we bring in a partnership, and we want to make sure it gets broad exposure. We don't want to speak with just one partner. Of course, we'll talk to a single partner if they offer us a lot of money — that's a different story — but we do want to make sure we've got a good partnership. And then we get true value for what we believe is really an asset that really keeps showing positive results here. We'll be really impactful in treating dry eye disease, as well as other diseases at the front of the eye. I mean, I don't think this product is limited to one indication.
Joe Pantginis
analystNo, absolutely. Fair enough. Thanks very much, and I'm looking forward to Friday.
Carl Spana
executiveYes, I believe we have an excellent group of individuals who have joined us to speak with you, and that excites us.
Operator
operatorAnd our next question comes from Michael Higgins at Ladenburg Thalmann. Go right ahead.
Michael Higgins
analystThank you, everyone. It seems many of the remarks regarding PL9643 are coming in for the KOL events, so I'll hold off on sharing mine. In that case, it appears you'd like to go into it in more depth, so I appreciate that. Thanks all the same.
Carl Spana
executiveAlright.
Operator
operatorThanks. That brings us to the end of the question-and-answer portion today, everyone. Right now, I'll hand things back over to Dr. Spana and Michael Higgins for any closing comments or anything further they'd like to add.
Carl Spana
executiveI believe you were referring to Steve Wills—that's fine. Mike, well, I think you need to add any remaining comments. Well, thanks, everyone, for joining and for the thoughtful questions. We keep achieving a great deal of progress here, and we're really enthusiastic about our future direction, not only in the ocular area but in other areas too. And while the near term is ocular, don't overlook the assets in ulcerative colitis. And there are a few other things we'll be examining too. For anyone on the call right now, or who listens to it, I think you can locate an invitation to Friday's webinar on the website, so please sign up. We have truly some of the finest people in the world that we're collaborating with, and they will be presenting the data, the trial design, where we're headed, and really the role of the melanocortin system in ocular inflammation. So there's quite a lot to learn, and I think it's quite an exciting time for us. So thank you, do be safe, and we look forward to Friday's call and then also to continuing to update you on our progress. Thanks.
Operator
operatorLadies and gentlemen, that brings today's conference to a close. Thank you for taking part. You can disconnect at this point.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Palatin Technologies, Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →This call discussed
For developers and AI pipelines
Programmatic access to Palatin Technologies, Inc. earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Palatin Technologies, Inc. or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.